James M. Frates, Chief Financial Officer at Amylyx Pharmaceuticals, Inc. (AMLX), sold 3,557 shares at $14.65 ($52K) on 2026-02-02, disclosed to the SEC on 2026-02-04.
Open-market sale of $52k AMLX by Chief Financial Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| Filing → |
| AMLX | SELL | 2026-01-08 | $37K | — | Filing → |
| AMLX | SELL | 2025-10-02 | $309K | — | Filing → |
| AMLX | SELL | 2025-04-02 | $38K | — | Filing → |